Spyre Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Investors need to see if the company is making progress and managing money responsibly.
These official documents show the company's complete financial position and help you understand business health.
Successful drug trial results increase the chance the medicine reaches patients and generates future profits.
Broader drug rights mean more potential uses and more opportunities to make money from the treatment.
Board changes and employee stock plans affect company leadership and how workers are incentivized.
Quarterly earnings reports let investors track whether the company is progressing toward profitability.
Official quarterly filings provide the full picture of company finances and operational performance.
Stocky reads Spyre Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Spyre Therapeutics, Inc.'s most recent tracked filing was a 8-K on 4 Aug 2026: Announces second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.